Lupus

What is Lupus?

Lupus is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues and organs. This can cause widespread inflammation and damage to various body systems, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain.

Types of Lupus

1. Systemic Lupus Erythematosus (SLE)

• Most common type of lupus.
• Affects multiple organ systems and can range from mild to severe.

2. Cutaneous Lupus

• Affects the skin and can cause rashes or lesions.
• Subtypes: Discoid lupus (chronic skin rashes), subacute cutaneous lupus (red, scaly patches).

3. Drug-Induced Lupus

• Caused by certain medications and usually resolves once the medication is stopped.
• Symptoms: Similar to those of SLE but typically less severe.

4. Neonatal Lupus

• Rare condition affecting infants born to mothers with certain autoimmune antibodies.
• Symptoms: Skin rash, liver problems, and in rare cases, congenital heart block.

Common Symptoms of Lupus

Symptoms can vary widely among individuals and may include:

• Fatigue
• Joint pain, stiffness, and swelling
• Butterfly-shaped facial rash across the cheeks and nose
• Skin rashes and lesions that worsen with sun exposure (photosensitivity)
• Fever
• Hair loss
• Raynaud's phenomenon: Fingers and toes turning white or blue in response to cold or stress
• Chest pain when taking deep breaths
• Headaches and cognitive difficulties

Causes and Risk Factors

• Genetic predisposition: Family history of lupus or other autoimmune diseases can increase the risk.
• Environmental triggers: Such as infections, sunlight, and certain medications.
• Hormonal factors: More common in women, particularly those aged 15-45, suggesting a link to estrogen.
• Ethnicity: More prevalent in people of African American, Hispanic, Asian, and Native American descent.

Diagnosis

• Medical history and physical examination: To evaluate symptoms and potential risk factors.
• Blood tests:
  • Antinuclear antibody (ANA) test: Common initial test for detecting autoimmune activity.
  • Other antibody tests: Such as anti-dsDNA and anti-Smith antibodies, which are more specific to lupus.
• Imaging tests: Such as X-rays or echocardiograms to detect organ involvement.
• Urinalysis: To check for kidney involvement by detecting proteins or red blood cells in urine.
• Skin or kidney biopsy: May be performed to confirm a diagnosis and determine the extent of the disease.

Treatment Options

• Medications:
  • Nonsteroidal anti-inflammatory drugs (NSAIDs): For joint pain and inflammation.
  • Antimalarial drugs: Such as hydroxychloroquine to help control lupus symptoms.
  • Corticosteroids: To reduce inflammation and manage severe symptoms.
  • Immunosuppressive drugs: Such as azathioprine and methotrexate to control immune system activity.
  • Biologic agents: Such as belimumab for more targeted treatment.
• Lifestyle changes:
  • Sun protection: Use sunscreen and wear protective clothing to reduce photosensitivity.
  • Balanced diet: Emphasize nutrient-rich foods to support overall health.
  • Regular exercise: Helps improve cardiovascular health and reduce joint stiffness.
  • Stress management: Techniques like yoga and meditation to manage stress, which can trigger flares.

Prevention and Management Strategies

• Avoid known triggers: Such as excessive sun exposure and certain medications.
• Follow treatment plans: Adhere to prescribed medication regimens and attend regular medical check-ups.
• Monitor symptoms: Keep track of symptoms and report any new or worsening signs to a healthcare provider.

Complications of Lupus

• Kidney damage (lupus nephritis): Can lead to kidney failure if not managed effectively.
• Heart and blood vessel issues: Increased risk of cardiovascular disease and inflammation of the heart (pericarditis).
• Lung involvement: Including pleuritis and potential lung damage.
• Blood disorders: Such as anemia, leukopenia, and thrombocytopenia.
• Nervous system problems: Seizures, headaches, and cognitive dysfunction.
• Infections: Due to weakened immune system function.

9. References & Research

Historical Background

The term "lupus" (Latin for wolf) was first used by the medieval physician Rogerius in the 13th century to describe erosive facial lesions. Moritz Kaposi distinguished the systemic form from the purely cutaneous disease in 1872. The LE cell phenomenon was discovered by Malcolm Hargraves in 1948, and the antinuclear antibody (ANA) test was developed in the 1950s, transforming diagnosis.

Key Research Papers

1. Tsokos GC. Systemic lupus erythematosus. New England Journal of Medicine. 2011;365(22):2110-2121.
2. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2019;78(6):736-745.
3. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nature Reviews Disease Primers. 2016;2:16039.
4. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus (BLISS-52). The Lancet. 2011;377(9767):721-731.
5. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis & Rheumatism. 2012;64(8):2677-2686.
6. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care & Research. 2012;64(6):797-808.
7. Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. American Journal of Medicine. 2006;119(8):700-706.
8. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2019;71(9):1400-1412.
9. Rahman A, Isenberg DA. Systemic lupus erythematosus. New England Journal of Medicine. 2008;358(9):929-939.
10. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Journal of the American Society of Nephrology. 2009;20(5):1103-1112.
11. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Annals of the Rheumatic Diseases. 2010;69(1):20-28.
12. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. New England Journal of Medicine. 2020;382(3):211-221.

Back to Table of Contents